Switch of Open-Source Automated Insulin Delivery (AID) System—AndroidAPS to Commercially Available AID Systems in Type 1 Diabetes: The Extension of the CODIAC Study
Authors' conclusion
The switch from AAPS to commercially available systems was not associated with a change in TIR. However, the use of AAPS was associated with a higher TITR, but also with a higher risk of hypoglycemia.
Study context
- Population
- Adults with T1D who voluntarily used AAPS; age 35 ± 11 years, HbA1c 6.4 ± 2.8%
- Participants
- 41 crossover-like phases
- Exposure
- Commercially available AID systems vs open-source AID AndroidAPS
- Control-IQ (CIQ)n = 25
- 780Gn = 16
- Outcome
- Time in range (TIR)
Methodological detailsopen-label, extension study, three 3-month phases (AAPS, commercial AID, AAPS)
- Open-label
- Extension study
- Three 3-month phases (AAPS, commercial AID, AAPS)
Main finding
As reported in the abstract
P = 0.31
Observational data: associations, not effects.
Further findings
| Outcome | AAPS | P value |
|---|---|---|
| HbA1cCommercial AID vs AAPS · comparable | 6.3 ± 2.7 % | P = 0.68 |
| Mmol/mol | 45.7 ± 6.2 | |
| Time in tight range (TITR)AAPS vs Commercial AID · significantly higher with AAPS | 66.38 ± 11.84 | P = 0.035 |
- HbA1c: Commercial AID 6.4 ± 3 % · mmol/mol 46 ± 8.8
- Time in tight range (TITR): Commercial AID 63.4 ± 11.77
Results after switching back to AAPS
- These results were consistent after switching back to AAPS
Safety
| Outcome | P value |
|---|---|
| Time in hypoglycemia <70 mg/dL [<3.9 mmol/L]Commercially available AID systems vs AAPS · significantly lower with commercially available AID systems · results consistent after switching back to AAPS | P < 0.001 |
Original publication
Switch of Open-Source Automated Insulin Delivery (AID) System—AndroidAPS to Commercially Available AID Systems in Type 1 Diabetes: The Extension of the CODIAC Study. Diabetes Technol Ther. Published 10 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →